COMPANY OVERVIEW

Annexon Bioscience's mission is to develop disease-modifying therapeutics for patients suffering with classical complement-mediated autoimmune, ophthalmic and neurodegenerative disorders.

---

LOCATION

South San Francisco, CA, USA

---

THERAPEUTIC AREAS

Autoimmune Disease

Neurodegenerative Disease

Ophthalmology

---

WEBSITE

https://www.annexonbio.com

---

CAREER WEBSITE

https://www.annexonbio.com/careers/

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Oct 9, 2019

Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX007 in Glaucoma

Sep 30, 2019

Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX005 in Guillain-Barré Syndrome

Sep 23, 2019

Annexon Biosciences Announces FDA Fast Track Designation for Novel C1q Inhibitor ANX005 for the Treatment of Guillain-Barré Syndrome

Jul 9, 2019

Annexon Biosciences Expands Senior Leadership as it Advances its Novel Complement Approach to Autoimmune and Neurodegenerative Disorders

Dec 19, 2018

Annexon Biosciences Closes $75 Million Financing

For More Press Releases

---